ClinicalTrials.gg
CompletedNCT00097084Updated Jan 27, 2017

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

A Phase 3 interventional study of insulin detemir and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 60 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Insulin Detemir · Diabetes Mellitus, Type 2.

Enrollment
15th of 43
324 · median 130
Started
2004
with 4 others
Phase 3
12 of 43
none open now
Registered
1st of 43
by date
Lead sponsor
28 of 43
Novo Nordisk A/S

Among the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 5 that started in 2004, is one of 12 in phase 3, and was the 1st registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin Detemir

Insulin Detemir: first FDA approval 2005 (LEVEMIR FLEXTOUCH), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 324 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes for at least 12 months
  • Treated with oral antidiabetic drugs or with any insulin regimen with or without oral antidiabetic drugs
  • of maximum 40 kg/m2
  • greater than or equal to 7.0% and less than or equal to 11.0%

Exclusion criteria

Exclusion Criteria:

  • Proliferative retinopathy or maculopathy
  • Recurrent major hypoglycaemia
  • Impaired hepatic or renal function
  • Cardiac problems or uncontrolled hypertension
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
324 participants (actual)
07

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: after 1 year trial period

Secondary outcomes

  1. Adverse events

  2. Body weight

  3. Hypoglycemia

  4. Blood glucose

  5. Insulin Treatment Satisfaction

08

Study locations

60 sites
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72204, United States
  • Novo Nordisk Investigational Site
    Inglewood, California 90301, United States
  • Novo Nordisk Investigational Site
    San Francisco, California 94143-0780, United States
  • Novo Nordisk Investigational Site
    Santa Ana, California 92705, United States
  • Novo Nordisk Investigational Site
    Spring Valley, California 91978, United States
  • Novo Nordisk Investigational Site
    Boca Raton, Florida 33433, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Lake Mary, Florida 32746, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32901, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32804, United States
  • Novo Nordisk Investigational Site
    Palm Harbor, Florida 34684, United States
  • Novo Nordisk Investigational Site
    Vero Beach, Florida 32960, United States
  • Novo Nordisk Investigational Site
    Athens, Georgia 30606, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Omaha, Nebraska 68114, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89119-6100, United States
  • Novo Nordisk Investigational Site
    Berlin, New Jersey 08009, United States
  • Novo Nordisk Investigational Site
    Asheville, North Carolina 28803, United States
  • Novo Nordisk Investigational Site
    Hermitage, Pennsylvania 16148, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75235, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-8858, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78229, United States
  • Novo Nordisk Investigational Site
    Newport News, Virginia 23606, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23249, United States
  • Novo Nordisk Investigational Site
    Tacoma, Washington 98405, United States
  • Novo Nordisk Investigational Site
    Espoo, 02740, Finland
  • Novo Nordisk Investigational Site
    Helsinki, 00260, Finland
  • Novo Nordisk Investigational Site
    Kurikka, FI-61300, Finland
  • Novo Nordisk Investigational Site
    Lahti, FI-15110, Finland
  • Novo Nordisk Investigational Site
    Lapua, FI-62100, Finland
  • Novo Nordisk Investigational Site
    Oulu, FI-90220, Finland
  • Novo Nordisk Investigational Site
    Turku, 20700, Finland
  • Novo Nordisk Investigational Site
    Brest, 29200, France
  • Novo Nordisk Investigational Site
    Le Mans, France
  • Novo Nordisk Investigational Site
    MONTPELLIER cedex 5, 34295, France
  • Novo Nordisk Investigational Site
    Nanterre, 92014, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    NEVERS cedex, 58033, France
  • Novo Nordisk Investigational Site
    Orleans, France
  • Novo Nordisk Investigational Site
    Paris, 75181, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Bergen, NO-5009, Norway
  • Novo Nordisk Investigational Site
    Notodden, NO-3675, Norway
  • Novo Nordisk Investigational Site
    Sarpsborg, 1723, Norway
  • Novo Nordisk Investigational Site
    Ski, NO-1400, Norway
  • Novo Nordisk Investigational Site
    Stavanger, 4011, Norway
  • Novo Nordisk Investigational Site
    Trondheim, NO-7030, Norway
  • Novo Nordisk Investigational Site
    Falun, 791 82, Sweden
  • Novo Nordisk Investigational Site
    Göteborg, 417 17, Sweden
  • Novo Nordisk Investigational Site
    Kalmar, 391 85, Sweden
  • Novo Nordisk Investigational Site
    Lund, 221 85, Sweden
  • Novo Nordisk Investigational Site
    Lund, 223 70, Sweden
  • Novo Nordisk Investigational Site
    Malmö, 214 26, Sweden
  • Novo Nordisk Investigational Site
    Motala, 591 85, Sweden
  • Novo Nordisk Investigational Site
    Oskarshamn, 572 28, Sweden
  • Novo Nordisk Investigational Site
    Uddevalla, 451 50, Sweden
  • Novo Nordisk Investigational Site
    Ängelholm, 262 91, Sweden
09

References and documents

Publications

  • Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008 Nov;30(11):1976-87. doi: 10.1016/j.clinthera.2008.11.001. PubMed 19108786 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2004
First posted
Nov 18, 2004
Start
Sep 2004
Primary completionActual
Dec 2005
CompletionActual
Dec 2005
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00097084
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 18, 2004
Start date
Sep 2004
Primary completion
Dec 2005
Completion
Dec 2005
Last update
Jan 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Detemir · Insulin Glargine · Insulin Aspart

Start the discussion